Latest news with #SamIfergan
Cision Canada
4 days ago
- Business
- Cision Canada
iGan Partners Invests in DOCSI to Transform Surgical Supply Chain Optimization
TORONTO, Aug. 7, 2025 /CNW/ - iGan Partners ( is pleased to announce its investment in DOCSI ( a Minneapolis-based company revolutionizing perioperative supply chain management through its mobile-first surgical preference dashboard. DOCSI helps hospitals and surgery centers digitize preference-card workflows, engage surgeons more effectively, and reduce supply costs — all without complex IT integrations. Its simple, data-driven platform is already used by large health networks, including Allina Health, to cut waste, standardize supplies, and drive savings. "At iGan Partners, we invest in solutions that deliver practical, measurable impact," said Sam Ifergan, Founder and Managing Partner at iGan Partners. "DOCSI's scalable platform aligns perfectly with our mission to modernize critical healthcare workflows—lowering costs, reducing variation, and empowering clinicians." "We're thrilled to welcome iGan Partners as a strategic investor," said Andrew DeLeeuw, CEO of DOCSI. "Their deep expertise in scaling healthcare technology companies will help us accelerate our mission to eliminate surgical waste, improve physician engagement, and simplify supply chain decisions for health systems." This investment reflects iGan's commitment to supporting entrepreneurs who are disrupting healthcare and driving meaningful improvements across the industry. About DOCSI Based in Minnesota, DOCSI is a surgeon-founded technology company that helps hospitals and surgery centers optimize supply chain efficiency by digitizing preference-card management and enhancing surgeon engagement. Its Surgical Preference Dashboard™ makes it easy to identify opportunities to reduce costs, standardize care, and limit waste with minimal IT burden. About iGan Partners iGan Partners is a North American venture capital firm focused on driving meaningful change in healthcare through investments in early- and growth-stage companies. We partner with visionary entrepreneurs who are building enterprise technologies to improve patient outcomes, increase operational efficiency, and deliver systemic transformation.
Cision Canada
05-06-2025
- Business
- Cision Canada
iGan Partners Leads Seed+ Financing for Cosm Medical to Advance Personalized Gynecological Devices
TORONTO, June 5, 2025 /CNW/ - iGan Partners is pleased to announce that it has led the first close of a Seed+ financing round for Cosm Medical, a medical device company modernizing pelvic health through personalized gynecological care. The round included new investor Spring Impact Capital and several angels, and will support Cosm's U.S. expansion, clinical validation, and commercial growth. Cosm's flagship platform, Gynethotics TM, combines medical imaging, AI-driven design software, and 3D printing to create custom vaginal devices – starting with pessaries – tailored to each patient's unique anatomy and needs. The solution addresses a widespread but underserved women's health issue: pelvic floor disorders, which affect up to half of all women in their lifetime. "Cosm is modernizing a long-overlooked space in women's health through a personalized, data-driven platform grounded in precision care," said Sam Ifergan, Founding Partner at iGan Partners. "We're excited to support their mission to improve outcomes and quality of life for millions of women." "At Cosm, we're not just building a product—we're redefining an entire category of women's health. Our Gynethotics™ platform is more than just technology; it's a commitment to precision, personalization, and dignity in care. With the support of iGan Partners and our investors, we're accelerating a future where women are no longer underserved – where every solution is tailored, and true innovation means changing lives. This is just the beginning." – Derek Sham, Founder & CEO of Cosm Medical. "We were impressed with Derek's experience in commercializing medical devices, as well as COSM's extraordinary team, depth of intellectual property and thoughtfulness of the go-to-market strategy, said Olivia Hornby, Managing Partner at Spring Impact Capital. "As impact investors, we were excited by COSM's mission of building customized and data centric Gynethotics solutions – providing better care for the huge percentage of women who suffer from pelvic floor disorders. Gynethotics TM pessaries are approved for sale in both Canada and the U.S., and Cosm is actively expanding its presence across North America. The company is also building its clinical dataset and advancing its product pipeline to support new applications beyond pessary support, including postpartum and post-surgical recovery. About Cosm Medical Cosm Medical is a medical device company developing a hardware and software platform to personalize the treatment of pelvic floor disorders (PFDs), such as incontinence and pelvic organ prolapse. Its first product, Gynethotics TM, is a made-to-measure gynecological prosthetics platform that combines imaging, AI, and 3D printing to improve pessary performance, enhance patient comfort, and reduce complications. Cosm is redefining care for a long-overlooked area of women's health through precision medicine and digital innovation. Learn more at About iGan Partners iGan Partners is a North American venture capital firm focused on investing in emerging leaders in medical technology and digital health. We partner with founders building transformative solutions to improve patient outcomes, reduce system inefficiencies, and enable the future of data-driven care. iGan provides capital and strategic support to early commercial-stage companies across MedTech, digital health, diagnostics, and health IT. Our team brings deep sector expertise, a strong cross-border network, and a track record of scaling healthcare ventures from early growth to successful exit. Learn more at
Associated Press
05-06-2025
- Business
- Associated Press
iGan Partners Leads Seed+ Financing for Cosm Medical to Advance Personalized Gynecological Devices
TORONTO, June 5, 2025 /PRNewswire/ - iGan Partners is pleased to announce that it has led the first close of a Seed+ financing round for Cosm Medical, a medical device company modernizing pelvic health through personalized gynecological care. The round included new investor Spring Impact Capital and several angels, and will support Cosm's U.S. expansion, clinical validation, and commercial growth. Cosm's flagship platform, GynethoticsTM, combines medical imaging, AI-driven design software, and 3D printing to create custom vaginal devices – starting with pessaries – tailored to each patient's unique anatomy and needs. The solution addresses a widespread but underserved women's health issue: pelvic floor disorders, which affect up to half of all women in their lifetime. 'Cosm is modernizing a long-overlooked space in women's health through a personalized, data-driven platform grounded in precision care,' said Sam Ifergan, Founding Partner at iGan Partners. 'We're excited to support their mission to improve outcomes and quality of life for millions of women.' 'At Cosm, we're not just building a product—we're redefining an entire category of women's health. Our Gynethotics™ platform is more than just technology; it's a commitment to precision, personalization, and dignity in care. With the support of iGan Partners and our investors, we're accelerating a future where women are no longer underserved – where every solution is tailored, and true innovation means changing lives. This is just the beginning.' – Derek Sham, Founder & CEO of Cosm Medical. 'We were impressed with Derek's experience in commercializing medical devices, as well as COSM's extraordinary team, depth of intellectual property and thoughtfulness of the go-to-market strategy, said Olivia Hornby, Managing Partner at Spring Impact Capital. 'As impact investors, we were excited by COSM's mission of building customized and data centric Gynethotics solutions – providing better care for the huge percentage of women who suffer from pelvic floor disorders. GynethoticsTM pessaries are approved for sale in both Canada and the U.S., and Cosm is actively expanding its presence across North America. The company is also building its clinical dataset and advancing its product pipeline to support new applications beyond pessary support, including postpartum and post-surgical recovery. About Cosm Medical Cosm Medical is a medical device company developing a hardware and software platform to personalize the treatment of pelvic floor disorders (PFDs), such as incontinence and pelvic organ prolapse. Its first product, GynethoticsTM, is a made-to-measure gynecological prosthetics platform that combines imaging, AI, and 3D printing to improve pessary performance, enhance patient comfort, and reduce complications. Cosm is redefining care for a long-overlooked area of women's health through precision medicine and digital innovation. Learn more at About iGan Partners iGan Partners is a North American venture capital firm focused on investing in emerging leaders in medical technology and digital health. We partner with founders building transformative solutions to improve patient outcomes, reduce system inefficiencies, and enable the future of data-driven care. iGan provides capital and strategic support to early commercial-stage companies across MedTech, digital health, diagnostics, and health IT. Our team brings deep sector expertise, a strong cross-border network, and a track record of scaling healthcare ventures from early growth to successful exit. Learn more at View original content to download multimedia: SOURCE iGan Partners
Yahoo
29-05-2025
- Business
- Yahoo
iGan Partners Invests in Cyborg to Advance Confidential AI for Regulated Industries
TORONTO, May 29, 2025 /CNW/ - iGan Partners is excited to announce an investment in Cyborg ( a pioneering company developing confidential AI infrastructure designed to meet the stringent privacy and compliance requirements of regulated industries such as healthcare. Cyborg's flagship product, CyborgDB, is the first vector database that enables fully encrypted inference—ensuring that data remains encrypted at rest, in transit, and during processing. This breakthrough allows organizations to leverage the power of AI without compromising data privacy, security, or regulatory compliance. "We're thrilled to partner with iGan Partners, whose deep expertise in healthcare and health-tech innovation aligns perfectly with our vision. iGan's strategic support will be instrumental in driving adoption of Cyborg's Confidential AI infrastructure, including our flagship product, CyborgDB, enabling healthcare and other regulated industries to securely unlock the full potential of artificial intelligence," said Nicolas Dupont, CEO of Cyborg. "At iGan Partners, we are committed to supporting transformative companies that address real-world challenges in healthcare," said Sam Ifergan of iGan Partners. "Cyborg's innovation in confidential AI infrastructure represents a foundational shift in how enterprises can safely adopt AI, and we are excited to support their growth." This investment reflects iGan's continued focus on empowering bold entrepreneurs who are reshaping the future of healthcare and healthcare data. This is iGan's fourth portfolio company in AI/Data, joining Segmed, Marble, and Meta. For more information about Cyborg, visit About iGan Partners iGan Partners is a North American venture capital firm focused on Medtech and healthcare innovation. We invest in companies that are redefining the future of healthcare, and our portfolio companies are solving some of its most pressing challenges. Learn more at View original content to download multimedia: SOURCE iGan Partners View original content to download multimedia:
Cision Canada
29-05-2025
- Business
- Cision Canada
iGan Partners Invests in Cyborg to Advance Confidential AI for Regulated Industries
TORONTO, May 29, 2025 /CNW/ - iGan Partners is excited to announce an investment in Cyborg ( a pioneering company developing confidential AI infrastructure designed to meet the stringent privacy and compliance requirements of regulated industries such as healthcare. Cyborg's flagship product, CyborgDB, is the first vector database that enables fully encrypted inference—ensuring that data remains encrypted at rest, in transit, and during processing. This breakthrough allows organizations to leverage the power of AI without compromising data privacy, security, or regulatory compliance. "We're thrilled to partner with iGan Partners, whose deep expertise in healthcare and health-tech innovation aligns perfectly with our vision. iGan's strategic support will be instrumental in driving adoption of Cyborg's Confidential AI infrastructure, including our flagship product, CyborgDB, enabling healthcare and other regulated industries to securely unlock the full potential of artificial intelligence," said Nicolas Dupont, CEO of Cyborg. "At iGan Partners, we are committed to supporting transformative companies that address real-world challenges in healthcare," said Sam Ifergan of iGan Partners. "Cyborg's innovation in confidential AI infrastructure represents a foundational shift in how enterprises can safely adopt AI, and we are excited to support their growth." This investment reflects iGan's continued focus on empowering bold entrepreneurs who are reshaping the future of healthcare and healthcare data. This is iGan's fourth portfolio company in AI/Data, joining Segmed, Marble, and Meta. For more information about Cyborg, visit
